OB/GYN opens MFM Clinical Trial Aimed at Improving Treatment of Fetal Arrhythmias

OB/GYN opens MFM Clinical Trial Aimed at Improving Treatment of Fetal Arrhythmias

Dr. Erika Peterson, Maternal-Fetal Medicine physician, and the Department of Obstetrics and Gynecology is excited to announce our participation in a new international multicenter clinical trial called aimed at improving the care of babies with fetal tachyarrhythmia and their mothers.

Fetal supraventricular tachyarrhythmias, or SVAs, occur when an unborn baby’s heart beats too fast. If allowed to continue for an extended period of time, these tachyarrhythmias may prevent the heart from pumping blood through the baby’s body normally. The baby may develop heart failure, buildup of fluid in the organs or under the skin, or may even die. To convert the baby’s heart back to a normal rhythm, doctors will typically prescribe one of two medications (or combinations of medications) for the mother to take. Which medication is used depends on what type of arrhythmia the baby has, but there is no information available indicating which option is best.

The Fetal Atrial Flutter and Supraventricular Tachycardia (FAST) Trial, sponsored by the Canadian Institutes of Health Research, hopes to determine which standard therapy for fetal SVA is most effective at converting the baby’s heart rate back to normal, and which therapy is better tolerated by both the mother and the baby. To do this, the FAST Trial will enroll pregnant women diagnosed with fetal SVA before 37 weeks gestation and randomly assign them to receive one of the two medications (or combinations of medications) that is standard treatment for the baby’s arrhythmia. The study will monitor mothers and babies for complications throughout the remainder of the pregnancy, up until 6 weeks after birth, and will determine which treatment resulted in better outcomes for both mothers and babies.

More information

For more information on this trial and other MFM trials, please see our Clinical Trials and Research for General OBGYN.

We are excited for the opportunity to help improve treatment of fetal SVAs through this important research!